Following an activating stimulus, CD4+T-helper cells that are Th1-polarized secrete IFN-γ, TNF-α, IL-2, and IL-12,[@bib1] which in turn induce upregulation of antigen processing, can induce expression of MHC class I and II molecules, and can induce other antigen display cofactors in neoplastic cells. Th1 CD4+T-helper cells also enhance antitumor immune responses by secretion of INF-γ, which in turn induces activation of macrophage cytotoxic activity.[@bib2]

Serum IgA, IgG, IgM, C3, C4, IL-6 and TNF-α were measured for 30 women, aged 27--70 years.[@bib3]

Serum IgA was significantly higher in patients who developed recurrence than patients who did not (p \< 0.05) ([Table 1](#tbl1){ref-type="table"}). Patients who developed recurrence exhibited a lower IgM level (158.81 ± 49.20 mg/dl) than those who did not (185.58 ± 68.40 mg/dl). However, it was statistically not significant ([Table 1](#tbl1){ref-type="table"}). A significantly higher C3 level (209.68 ± 71.71 mg/dl) was observed in patients who developed disease recurrence than those who did not (151.77 ± 42.78 mg/dl) (P \< 0.05) ([Table 1](#tbl1){ref-type="table"}).

Patients who developed recurrence exhibit a higher C4 level than patients who did not; but it was statistically not significant ([Table 1](#tbl1){ref-type="table"}). Patients who developed recurrence exhibit a significantly higher IL-6 level (284.16 ± 33.97 pg/ml) than those who did not (191.58 ± 74.78 pg/ml) (P \< 0.05) ([Table 1](#tbl1){ref-type="table"}).

Patients who develped recurrence showed a significantly higher TNF-α level (484.32 ± 357.02 pg/ml) than those who did not (166.41 ± 122.88 pg/ml) (P \< 0.05) ([Table 1](#tbl1){ref-type="table"}).

The IgA elevation reflects the load and activity of the melignant cells through host immune modulation or secretion of IgA by their own cells. This gives serum IgA a novel role in breast cancer patients prognosis. Since complement system has been activated through the calssical pathway,[@bib5] C3 can be beneficial in breast cancer prognosis and patients follow up during chemotherapy. IL-6 has an important role in tumour growth and metastasis and can illustrate the extent and the subclinical spread of the disease. Thus, IL-6 can be an important prognostic and predictive marker, as well as a vital treatment target in breast cancer patients. There is significant greater TNF-α level for patients who develop recurrence, in comparison to those who did not. That would be in consistence with the work of Nenova et al.,[@bib6] who revealed that cancer recurrence for patients exhibited TNF-α enhancement after third chemotherapy cycle. Therefore, serum TNF-α could be used clinically as a useful tumour marker for disease extent and outcome of breast cancer. In conclusion, serum IgA, C3, IL-6 and TNF-α can be used as a predictors for breast cancer recurrence.

###### 

Immunological parameter after three cycles of chemotherapy of the patients who developed recurrence and patients who didn\'t develop recurrence.

  Parameter       Recurrence group (mean ± S.D)   Non recurrence group (mean ± S.D)   Significance
  --------------- ------------------------------- ----------------------------------- --------------
  IgG (mg/dl)     1483.36 ± 711.73                1213.57 ± 511.03                    NS
                                                                                      
  IgA (mg/dl)     529.38 ± 123.77                 327.36 ± 180.58                      \< 0.05
                                                                                      
  IgM (mg/dl)     158.81 ± 49.20                  185.58 ± 68.40                      NS
                                                                                      
  C3 (mg/dl)      209.68 ± 71.71                  151.77 ± 42.78                       \< 0.05
                                                                                      
  C4 (mg/dl)      43.68 ± 22.26                   31.62 ± 11.65                       NS
                                                                                      
  IL-6 (pg/ml)    284.16 ± 33.97                  191.58 ± 74.78                       \< 0.05
                                                                                      
  TNF-α (pg/ml)   484.32 ± 357.02                 166.41 ± 122.88                      \< 0.05
